Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

plications ("ANDAs") for generic versions of OFIRMEV; the potential that Cadence may be required to continue intellectual property litigation for substantial lengths of time or file additional lawsuits to defend its patent rights from challenges by companies that have submitted ANDAs for generic versions of OFIRMEV, and the substantial costs associated with such lawsuits; the potential introduction of generic competition to OFIRMEV in the event Cadence is unsuccessful in current or future intellectual property litigation; Cadence's dependence on its licensors for the maintenance and enforcement of its intellectual property rights; the potential product liability exposure associated with pharmaceutical products such as OFIRMEV and other products Cadence may in-license or acquire; Cadence's ability to fully comply with numerous federal, state and local laws and regulatory requirements that apply to its commercial activities; public concern regarding the safety of drug products such as OFIRMEV, which could result in the implementation by regulatory agencies of new requirements to include unfavorable information in the labeling for OFIRMEV; the risk that Cadence may not be able to raise sufficient capital when needed, or at all; and other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic reports and other filings made with the Securities and Exchange Commission from time to time. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Cadence® and OFIRMEV® are trademarks of Cadence Pharmaceuticals, Inc. Contact:

William R. LaRue

Kelli FranceSVP & Chief Financial Officer

Media RelationsCadence
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... (NASDAQ: ONCE ) announced today that members ... and Company Health Care Conference on Wednesday, March 4, ... Copley Place. To access the live webcast ... please visit the "Upcoming Events" section within the "News ... www.sparktx.com .  A replay of the webcast will ...
(Date:2/26/2015)... Feb. 26, 2015 Caris Life Sciences® ... the 2015 Genitourinary Cancers Symposium in ... utility of tumor profiling. Both studies utilized Caris ... service, to identify biomarkers that shed light on ... small cell bladder cancer (SCBC). ...
(Date:2/25/2015)... Calif. , Feb. 25, 2015 ... nootropic drink, is featured in this week,s Power ... cnbc.com/id/102454724 , to discuss the company,s traction and ... offering through the crowd funding site CircleUp. ... novel products that are validated by neurotechnology, while ...
(Date:2/25/2015)... 2015 Market Publishers Ltd is happy ... by 9Dimen Research have been recently uploaded to its ... Market Research Report . This research report provides wealth ... the world adhesive mortar industry as well as includes ... major regional markets. It focuses on the main regions ...
Breaking Biology Technology:Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 3Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 4Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 5CNBC's Power Lunch Features Neurotechnology Start-up truBrain 2New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 2New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 3New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 4
... MADISON The push to amend the Wisconsin Constitution to ... in one of the states longest books the need ... a Taxpayer Bill of Rights is a best-seller or a ... Wisconsin changes how government raises and spends money. , ,Republican ...
... Information Networks Corp . President Paul Shain spoke ... of Accelerate Madisons monthly meeting. According to Shain, Berbees unique ... of the dot-com era as other information technology-focused companies failed. ... company was founded on the dogma of creating an environment ...
... who signs the paychecks in your organization. Most of us ... to whom. We might even know one or two board ... you much about who your IT staff is really working ... members become moles in your organization as they further the ...
Cached Biology Technology:Debate over Taxpayer Bill of Rights shows need for true tax reform 2Berbees success is based on companys history and culture 2Berbees success is based on companys history and culture 3Berbees success is based on companys history and culture 4Who does your IT staff work for? 2Who does your IT staff work for? 3
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition ... report to their offering. , The primary ... is who she/he is claiming to be, and for this ... physical characteristics, such as fingerprint, hand or palm print, iris, ...
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... MD The Federation of American Societies for ... for the Science Research Conference (SRC): Mechanism and ... FASEB Science Research Conference on Mechanism and Regulation ... in Saxton Rivers, VT. The "Vermont Transcription Meeting," ...
... Institute (UPCI) researchers have uncovered a technique to halt the growth ... new anti-cancer therapy. When deprived of a key protein, ... in the cover story of the February issue of the ... by a grant from the National Institutes of Health. ...
... of antibody-producing cells, a finding that could lead to ... of control, such as myeloma and chronic immune disorders. ... critical for keeping this vital immune cell population alive ... Hall Institute. Associate Professor David Tarlinton, Dr Victor Peperzak ...
Cached Biology News:Pitt researchers reveal mechanism to halt cancer cell growth, discover potential therapy 2Immune cell 'survival' gene key to better myeloma treatments 2